




| | | | |
|---------------------------------|---|---------------------------|---------------------------|
| | | EMLc | ATC codes: L01CA02 |
| Indication | Ewing sarcoma of bone and articular cartilage of unspecified sites | ICD11 code: 2C22.Z | |
| INN | Vincristine | | |
| Medicine type | Chemical agent | | |
| List type | Complementary (EML) (EMLc) | | |
| Formulations | Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate) ; 5 mg in vial (vincristine sulfate) ; 1 mg per mL in vial (vincristine sulfate) ; 2 mg per 2 mL in vial (vincristine sulfate) | | |
| EML status history | First added in 2015 (TRS 994) Changed in 2021 (TRS 1035) | | |
| Sex | All | | |
| Age | Also recommended for children | | |
| Therapeutic alternatives | The recommendation is for this specific medicine | | |
| Patent information | Patents have expired in most jurisdictions Read more about patents .  | | |
| Tags | Cancer | | |
| Wikipedia | Vincristine  | | |
| DrugBank | Vincristine  | | |

Summary of evidence and Expert Committee recommendations

The Expert Committee recommended the addition of new strength formulations of vincristine IV injection (1mg/mL and 2 mg/2mL) to the EML and EMLc.

[Expert Committee report](#) 

